Abstract
Tension-type headache (TTH) is a common disorder, with inespecific clinical characteristics and terapheutic schemes. TTH is a primary headache with a 4:5 male: female proportion, and is most prevalent between 30 and 39 years. It affects 78 per cent of the population and its treatment represents high costs. The diagnosis is based on the presence of pain without other findings observed in other primary headaches. The pain is usually bilateral, opressive or as a sensation of heaviness and it is not related to migraine symptoms. TTH should be distinguished from other headaches such as migraine, new daily chronic headache, cervicogenic headache, and headache secondary to analgesics overuse. The pathophysiology of TTH is multifactorial, involving central and peripheral mechanisms (sensibilization). The most important clinical findings in TTH are an increase of pericraneal myofascial sensitivity and an increase of muscular contraction on palpation. There are also involved emotional factors due to modifications of the lymbic system, increase in vascular tone caused by the hyperactivity of the sympathetic system, changes in intracraneal pressure of cerebrospinal fluid or intracraneal venous system, and failures in supraspinal inhibition due to serotoninergic system dysfuction. The treatment of TTH is based on pharmacological abortive and prophylactic measures, and non-pharmacologycal therapies.
References
- Antonaci F, Fredricksen TA, Sjaastad O. Cervicogenic Headache: Clinical presentation, diagnostic criteria and differential diagnosis. Curr Pain Headache rep 2001; 5: 387-392.
- Ashina M, Simonsen H, Bendtsen L, Jensen R, Olensen J. Glyceryl trinitrate may trigger endogenous nitric oxide production in patients with chronic tension-type headache. Cephalalgia 2004; 24: 967-972.
- Ashina M, Stallknecht B, Bendtsen L, et al. In vivo evidence of altered skeletal muscle blood flow in chronic tension-type headache. Brain 2002; 125: 320-326.
- Ashina M. Neurobiology of chronic tension-type headache. Cephalalgia 2004; 24: 161-172.
- Autret A, Unger PH, EURAXI group, Lesaichot JL. Naproxen sodium versus ibuprofen in episodic tension headache. Cephalalgia 1997; 17: 446.
- Bendtsen L. Central sensitization in tension-type headache. Possible pathophysiological mechanisms. Cephalalgia 2000; 20: 486-508.
- Bigal ME, Bordini CA, Speciali JG. Intravenous dipyrone for the acute treatment of episodic tension-type headache. A randomized, placebo-controlled, double-blind study. Brazilian Journal of Medical and Biological Research 2002; 35: 1139-1145.
- Brandes JL, Saper JR, Diamond M, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965-973.
- Burstein R, Cutrer MF, Yarnitsky D. The development of Cutaneous allodynia during a migraine attack: Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: 1703-109.
- Burstein R, Jakubowski M. Implications of multimechanism therapy: when to treat? Neurology 2005; 64 (Suppl 2): S16-S20.
- Bussone G, Grazzi L, D’ Amico D, Leone M, Andrasik
F. Biofeedback- associated Relaxation training for young adolescents with tension-type headache: A controlled Study. Cephalalgia 1998; 18: 463-467.
- Campo-Arias A. Antidepresivos en la profilaxis de la migraña: Una aproximación. Rev Neurol 2004; 38: 864-868.
- Da Cunha matta AP, Moreira Filho PF. Sintomas depressivos e ansiedade em pacientes com cefaleia do tipo tensional crônica e episodica. Arq Neurosiquiatr 2003; 61: 991-994.
- Dahlöf CGH, Jacobs LD. Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. Cephalalgia 1996; 16: 117-123.
- d’Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39: 716-719.
- Diamond S, Freitag FG, Balm TK, Berry DA. The use of a combination agent of ibuprofen and caffeine in the treatment of episodic tension-type headache. Cephalalagia 1997; 446.
- Durham PL, Cady R, Cady R. Regulation of Calcitonin- Gene Related Peptide secretion from Trigeminal nerve cells by Botulinum Toxin type A: Implications for migraine therapy. Headache 2004; 44: 35-43.
- Freitag FG. Preventive treatment for migraine and tension-type headaches: Do drugs having effects on muscle spasm and tone have a role?. CNS Drugs 2003; 17: 373-381.
- Fumal A, Schoenen J. Chronic daily headache. Goadsby PJ, Silberstein SD, Dodick DW, eds. Chronic daily headache for clinicians. Hamilton, Ontario, Canada.BC Decker Inc, 2005; 5: 57-64.
- Hannerz J, Jogestrand T. Relationship between chronic tension-type headache, cranial hemodynamics, and cerebrospinal pressure: Study involving provocation with sumatriptan. Headache 2004; 44: 154-159.
- Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd Ed. Cephalalgia. 2004; 24(suppl 1): 9-160.
- Holroyd KA, O’Donell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson BW. Management of chronic tension- type Headache with tricyclic antidepressant medication, stress-management therapy, and their combination. JAMA 2001; 2208-2215.
- Holroyd KA, Stensland M, Lipchik GL, Hill KR, O’Donnell FS, Cordingley G. Psychosocial correlates and impact of chronic tension-type headache. Headache 2000; 40: 3-16.
- Jensen R, Bendtsen L, Olensen J. Muscular factors are of importance in tension-type headache. Headache 1998; 38: 10-17.
- Jensen R. Peripheral and central mechanisms in tension-type headache: An update. Cephalalgia 2003; 23 (Suppl 1): 49-52.
- Krusz JC. Prophylaxis for chronic daily headache and chronic migraine with neuronal stabilizing agents. Curr Headache Reports 2002; 1: 230-235.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.